Article Details

Olaparib monotherapy 'true paradigm shift' in biochemically recurrent prostate cancer

Retrieved on: 2024-08-22 16:49:01

Tags for this article:

Click the tags to see associated articles and topics

Olaparib monotherapy 'true paradigm shift' in biochemically recurrent prostate cancer. View article details on hiswai:

Excerpt

Disclosures: AstraZeneca supported this study. Antonarakis reports personal fees or grants from AstraZeneca, Clovis Oncology, Eli Lilly & Co ...

Article found on: www.healio.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up